API Support
NASH Drug Discovery
8 months ago by ge
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage caused by fat accumulation. NASH can progress to fibrosis, cirrhosis, or hepatocellular carcinoma. Developing effective NASH therapies is challenging due to its complex pathophysiology, which involves metabolic, inflammatory, and fibrotic processes.